Introduction
============

Lung cancer remains the highest incidence of all cancers and the leading cancer-related death worldwide.[@b1-dddt-11-3435] Histopathologically, the majority of lung cancer (about 85%) are classified as non-small-cell lung cancer (NSCLC).[@b2-dddt-11-3435] Most patients with NSCLC (\~80%) are diagnosed with locally advanced or metastatic disease.[@b3-dddt-11-3435] Currently, platinum-based doublet chemotherapy is the standard of care for first-line therapy.[@b4-dddt-11-3435]--[@b6-dddt-11-3435] However, outcomes of advanced NSCLC is disappointing, with 5-year overall survival (OS) \<5%. Clearly, novel anti-cancer agents or treatment strategies are needed to improve the survival of these patients.

In order to sustain a reduced tumor size and relieve tumor-related symptoms, maintenance therapy has emerged as a novel therapeutic strategy for advanced NSCLC.[@b7-dddt-11-3435]--[@b9-dddt-11-3435] Maintenance therapy can be classified into 2 types: switch maintenance therapy and continuous maintenance therapy. Continuation maintenance is defined as keeping ongoing administration 1 or more drugs (combination maintenance) used in first-line regimen; while switch maintenance generally introduces an additional agent immediately after completion of 4 to 6 cycles of first-line chemotherapy. Several published meta-analyses have demonstrated that maintenance therapy with either a continuation or a switch strategy significantly increased progression-free survival (PFS) and OS in comparison with controls, but more incidences of toxicities are observed in maintenance therapy group.[@b10-dddt-11-3435]--[@b15-dddt-11-3435] Based on these published data, maintenance therapy has been recommended by the US Food and Drug Administration in advanced NSCLC after first-line chemotherapy.[@b16-dddt-11-3435] However, to our best knowledge, the role of maintenance therapy in the treatment of elderly NSCLC remains undetermined. As a result, we conducted this systematic review and meta-analysis to assess the overall efficacy of maintenance therapy in this patient population with advanced NSCLC.

Materials and methods
=====================

Study design
------------

We performed this systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement guidelines 2009.[@b17-dddt-11-3435]

Search strategy
---------------

We conducted a comprehensive literature search of public databases, including PubMed, EMBASE, and the Cochrane library (up to April 30, 2017). Relevant search keywords included the followings: "non-small-cell lung cancer," "maintenance therapy," and "randomized controlled trials (RCTs)." No language restriction was administered. We also conducted a manual search of conference proceedings. All results were input into Endnote X7 reference software (Thomson Reuters, Stamford, CT, USA) for duplication exclusion and further reference management.

Study selection
---------------

Clinical trials that met the following criteria were included: 1) prospective Phase II or III trials involving NSCLC patients; 2) patients received maintenance therapy; and 3) available survival data regarding elderly NSCLC patients. If multiple publications of the same trial were retrieved or if there was a case mix between publications, only the most recent publication (and the most informative) was included.

Data extraction
---------------

Two independent investigators conducted the data abstraction, and any discrepancy between the reviewers was resolved by consensus. The following information was extracted for each study: first author's name, year of publication, trial phase, number of enrolled subjects, treatment arms, median age, median PFS, and OS.

Outcome measures
----------------

A formal meta-analysis was conducted using Comprehensive Meta-Analysis software (Version 2.0; Biostat, Englewood, NJ, USA). The outcome data were pooled and reported as hazard ratio (HR). The primary outcome of interest was OS and secondary outcomes PFS in elderly patients with advanced NSCLC.

Statistical analysis
--------------------

All statistical analyses were performed by using Version 2 of the Comprehensive Meta-Analysis program. Between-study heterogeneity was estimated using the *χ*^2^-based Q statistic.[@b18-dddt-11-3435] The *I*^2^ statistic was also calculated to evaluate the extent of variability attributable to statistical heterogeneity between trials. If heterogeneity existed, data were analyzed using a random-effects model based on DerSimonian and Laird method. In the absence of heterogeneity, a fixed-effects model was used based on Mantel-Haenszel Method. HR \>1 reflected more deaths or progression in maintenance regimens group, and vice versa. A statistical test with a *p*-value \<0.05 was considered significant. Study quality was assessed by using the Jadad 5-item scale that included the randomization, double blinding, and withdrawals; the final score was reported between 0 and 5.[@b19-dddt-11-3435]

Results
=======

Search results
--------------

We initially found 210 relevant citations of maintenance therapy in NSCLC patients. After excluding review articles, Phase I studies, case reports, editorial, letters, commentaries, meta-analyses and systematic review ([Figure 1](#f1-dddt-11-3435){ref-type="fig"}), we selected 7 prospective RCTs,[@b20-dddt-11-3435]--[@b26-dddt-11-3435] and 2 studies with update results of previously published trials (PARAMOUNT[@b22-dddt-11-3435] and AVAPERL[@b21-dddt-11-3435]). Finally, a total of 5 trials were included for analysis in the present study. A total of 2,724 patients from 5 RCTs were included for analysis, with 897 patients aged ≥65 years and 1,577 patients aged \<65 years. [Table 1](#t1-dddt-11-3435){ref-type="table"} listed the baseline characteristics of patients and studies. The quality of each included study was roughly assessed according to Jadad scale, and 4 of the 5 RCTs were double-blind placebo-controlled trials, thus had Jadad score of 5. Another Phase III trial was an open-label controlled trial that had a Jadad score of 3.

Single-agent maintenance therapy in elderly patients
----------------------------------------------------

Two trials reported PFS data of single-agent maintenance therapy in elderly patients. The pooled HR for PFS demonstrated that the single-agent maintenance therapy in elderly patients significantly improved PFS giving HR 0.65 (95% CI: 0.43--0.98, *p*=0.04, [Figure 2](#f2-dddt-11-3435){ref-type="fig"}), in comparison with placebo. There was moderate heterogeneity between trials (*I*^2^=68.0%, *p*=0.077), and the pooled HR for PFS was performed by using random-effects model. Three trials reported OS data of single-agent maintenance therapy in this patient population. The pooled HR for OS showed that the single-agent maintenance therapy significantly improved OS giving HR 0.81 (95% CI: 0.68--0.97, *p*=0.024, [Figure 2](#f2-dddt-11-3435){ref-type="fig"}), in comparison with placebo.

Combination maintenance therapy in elderly patients
---------------------------------------------------

Two included trials comparing combination versus single-agent maintenance therapy reported survival data of elderly patients. The pooled HR for PFS demonstrated that combination maintenance therapy in elderly patients significantly improved PFS giving HR 0.67 (95% CI: 0.53--0.85, *p*=0.01, [Figure 3](#f3-dddt-11-3435){ref-type="fig"}), in comparison with singe agent maintenance therapy. However, no survival benefit was observed in combination maintenance in elderly patients (HR 1.05, 95% CI: 0.60--1.83, *p*=0.86).

Publication bias
----------------

We did not perform publication bias analysis due to limited RCTs in the present study.

Discussion
==========

Until now, platinum-based doublet chemotherapy represented the gold standard in the treatment of advanced NSCLC, but with modest improvement in OS. Previous studies had demonstrated that prolongation of platinum-containing chemotherapy yielded no survival benefit and exposed patients to a higher risk of severe side effects. A meta-analysis conducted by Rossi et al[@b27-dddt-11-3435] also confirmed that 4 courses of platinum-based treatment were the optimal duration of first-line chemotherapy. During the past decades, maintenance therapy for patients who achieved at least stable disease after first-line treatment has been extensively investigated to improve outcomes of advanced NSCLC patients. In fact, 5 meta-analyses[@b13-dddt-11-3435],[@b15-dddt-11-3435],[@b28-dddt-11-3435]--[@b30-dddt-11-3435] have been conducted to pool the overall results of randomized trials assessing maintenance therapy in advanced NSCLC patients. All these meta-analyses show that maintenance therapy exposes patients to an increased risk of toxicity. Regarding effectiveness, single agent maintenance strategies demonstrate an improvement in PFS and OS in comparison with placebo. Additionally, combined maintenance therapy significantly improves PFS but not OS when compared with single agent maintenance. However, to our best knowledge, these are no systematic review and meta-analysis to comprehensively assess the role of maintenance therapy in the treatment of elderly NSCLC patients.

Our study included a total of 897 patients aged ≥65 years for analysis. The pooled results demonstrated that single-agent maintenance therapy in elderly NSCLC patients significantly improved PFS (HR 0.65) and OS (HR 0.81) in comparison with placebo. In addition, doublet maintenance therapy significantly improved PFS (HR 0.81), but not OS (HR 1.05) in comparison with single-agent maintenance therapy. One possible explanation for this finding is that age may limit the aggressive maintenance treatment for elderly patients with advanced NSCLC, and elderly patients might have a slightly worse tolerance to combined maintenance therapy. Although we could not assess the toxicities of maintenance therapy in the present study, several previous studies have demonstrated an increased risk of toxicity with maintenance therapy in patients \>65 years. In 1 study, patients who received pemetrexed maintenance therapy were more likely to have grade 3/4 toxicity (19% versus 10%), with the most common grade 3 toxicity being anemia and neutropenia.[@b31-dddt-11-3435]

Limitations
===========

Several limitations exist in this analysis. First, this meta-analysis only considers published literature, and a meta-analysis of individual level data might define more clearly treatment benefits in specific subgroups. For instance, elderly patients are more likely to have comorbid conditions, and we are unable to investigate whether the survival benefit is similar in elderly patients with or without comorbid conditions. Second, none of the included trials report the toxicities of maintenance therapy in elderly patients. Thus, we could not answer whether the use of maintenance therapy in this patient population would increase the toxicities in comparison with controls. Third, there is still no general agreement on the definition of the elderly population. In the present study, all the included trials define elderly patients as \>65 years. Finally, switch and continuous maintenance therapies are combined in the meta-analysis, which might increase the heterogeneity among included trials. In addition, our study includes different drugs with different mechanisms for analysis, which might be another source of heterogeneity. Although significant clinical heterogeneity of the meta-analysis could make the interpretation of a meta-analysis more problematic, but clinical heterogeneity might improve the generalizability of the observed heterogeneity.

Conclusion
==========

In conclusion, this is the first meta-analysis specifically assessing the efficacy of maintenance therapy in the treatment of elderly patients with advanced NSCLC. The results of our study suggest that single-agent maintenance offers an improved PFS and OS in elderly NSCLC patients who have not progressed (ie, complete response, partial response, or stable disease) after at least 4 cycles of platinum-based chemotherapy. Further studies are recommended to investigate the efficacy and toxicities of combined maintenance therapy in the treatment of elderly NSCLC patients.
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###### 

Baseline characteristics of 5 included trials

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study/year                          Phase   No of elderly patients   Cut-off of age   First-line therapy                            Maintenance arm             Type of maintenance                           Primary endpoint   Jadad score
  ----------------------------------- ------- ------------------------ ---------------- --------------------------------------------- --------------------------- --------------------------------------------- ------------------ -------------
  Cappuzzo et al[@b26-dddt-11-3435]   III     296                      ≥65              Platinum-doublet chemotherapy                 Erlotinib\                  EGFR-targeted therapy/switch maintenance      PFS                5
                                                                                                                                      Placebo                                                                                      

  Barlesi et al[@b24-dddt-11-3435]    III     72                       ≥65              Platinum-doublet chemotherapy + bevacizumab   Bevacizumab + Pemetrexed\   AI-targeted therapy/continuous maintenance    PFS                3
                                                                                                                                      Bevacizumab                                                                                  

  Johnson et al[@b23-dddt-11-3435]    III     184                      ≥65              Platinum-doublet chemotherapy + bevacizumab   Bevacizumab + erlotinib\    AI-targeted therapy/continuous maintenance    PFS                5
                                                                                                                                      Bevacizumab + placebo                                                                        

  Paz-Ares et al[@b22-dddt-11-3435]   III     189                      ≥65              Platinum-doublet chemotherapy                 Pemetrexed\                 Cytotoxic agents/continuous maintenance       OS                 5
                                                                                                                                      Placebo                                                                                      

  Butts et al[@b20-dddt-11-3435]      III     156                      ≥65              Chemoradiotherapy                             Tecemotide\                 Immunotherapy/switch continuous maintenance   OS                 5
                                                                                                                                      Placebo                                                                                      
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** AI, aromatase inhibitor; EGFR, epidermal growth factor receptor; PFS, progression-free survival; OS, overall survival.
